NCT04644614

Brief Summary

MS is a technology developed to non-invasively stimulate the central and peripheral nervous system, is applied in the treatment of UI. The MS technique aims to directly stimulate the pelvic floor muscles and sacral roots in the treatment of UI (3,4). MS is a more acceptable, relatively painless, non-invasive and suitable electrical treatment method for patients with UI (5). Data from studies suggest that MS may be beneficial for patients with UI after RP (1,2,5,6,7). In the literature, there are only 3 randomized controlled trials evaluating MS efficacy using a magnetic chair in patients with UI after RP (1,6,8) and one of them was published in Korean (6) and two of them in English(1,8). In these studies, MS was compared with pelvic floor muscle exercises (PFME) or electrical stimulation (ES) (intra-anal).Yokoyama et al.reported that MS and ES treatments had shown to provide earlier continence compared to the control group after RP. MS and ES are recommended as options for patients who want rapid recovery of postoperative UI(1). Liu et al reported that MS was more effective than PTKE on incontinence symptoms and quality of life (8). However, as far as we know, there is no prospective randomized sham-controlled study evaluating the effectiveness of MS in patients with post-RP UI. In addition, there are no suggestions regarding MS in the guidelines on urinary incontinence management due to insufficient data (9). In this study, sham-controlled efficacy of MS will be evaluated in patients with UI after RP. Our study is the first prospective randomized controlled trial comparing MS and Sham MS efficacy in patients with UI after RP. In this study, we aimed to evaluate the effectiveness of MS on incontinence related clinical parameters, quality of life, sexual functions, depression and anxiety in patients with UI after RP.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 20, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 25, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2021

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2023

Completed
Last Updated

November 1, 2022

Status Verified

October 1, 2022

Enrollment Period

2.1 years

First QC Date

November 20, 2020

Last Update Submit

October 31, 2022

Conditions

Keywords

urinary incontinenceradical prostatectomymagnetic stimulation

Outcome Measures

Primary Outcomes (1)

  • Incontinence episodes

    Patients with a 50% or greater reduction in incontinence episodes were consider improvement

    6 weeks

Secondary Outcomes (8)

  • Severity of incontinence

    6 weeks

  • Three-day Bladder Diary

    6 weeks

  • Quality of Life - Incontinence Impact Questionnaire (IIQ-7)

    6 weeks

  • Level of sexual function - International Index of Erectile Function (IIEF)

    6 weeks

  • Level of Anxiety and Depression - Hospital Anxiety and Depression Scale (HAD)

    6 weeks

  • +3 more secondary outcomes

Study Arms (2)

Group 1: Magnetic Stimulation

ACTIVE COMPARATOR

Patients will be instructed to sit in a magnetic coil chair. Magnetic flux is generated in this field. This current stimulates the nerve or muscle of the pelvic floor. To administer MS, a stimulation amplitude of 200 μs and a repetition of 10 Hz for 10 minutes, 2 minutes rest in between, 50 Hz for 10 minutes (20 minutes total), 5 seconds on / 5 seconds off, in accordance with device literature will be adjusted to produce maximum stimuli with the cycle. During each treatment session, the device will be adjusted to receive patients the current intensity gradually increasing, reaching the maximum stimulation intensity.

Device: Magnetic Stimulation - Armchair type

Group 2: Sham Magnetic Stimulation

SHAM COMPARATOR

The Sham MS treatment program will be the same as active MS in terms of duration, frequency, current duration, current intensity and general patient experience. The same magnetic chair will be used for both groups. Sham therapy application will be applied by the coordinator of the study by placing a thin deflector lead / aluminum coated plate on the magnetic coil of the magnetic chair that prevents the magnetic flux from penetrating into the patient. During both applications, the patients will be exposed to the same sound, vibration sensation and lighting of the device.

Device: Magnetic Stimulation - Armchair type

Interventions

MS and Sham MS will be applied two days a week, 20 minutes a day, for 8 weeks, a total of 16 sessions.

Also known as: NovaMag NT-60
Group 1: Magnetic StimulationGroup 2: Sham Magnetic Stimulation

Eligibility Criteria

Age18 Years - 80 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsMen with urinary incontinence after radical prostatectomy
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old
  • Men with RP with incontinence over ≥50 g / 24 hours
  • Patients within 1 month to 1 year after catheter removal
  • Willingness to complete and do the quality of life scale
  • Understanding procedures, benefits, and possible side effects
  • Being able to give written, informed consent

You may not qualify if:

  • History of conservative treatment after RP including MS
  • Previous urological surgery history
  • UI history before RP
  • Transurethral resection of the prostate due to benign prostatic hyperplasia
  • Patients receiving radiotherapy
  • Presence of urinary tract infection
  • Heart failure, presence of a pacemaker, implanted defibrillator
  • Continuing treatment for arrhythmias
  • Undiagnosed lower abdominal pain
  • Electronic device or metallic implant applied to the areas between the lumbar region and lower extremities
  • Use of drugs that may affect bladder function (antimuscarinic, duloxetine, tricyclic antidepressant, etc.)
  • History of neurogenic bladder, peripheral or central neurological pathology

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Necmettin Yildiz

Denizli, 20100, Turkey (Türkiye)

RECRUITING

Related Publications (1)

  • Unal B, Sarsan A, Yildiz N, Alkan H. Efficacy of Magnetic Stimulation in Men With Urinary Incontinence After Radical Prostatectomy: A Randomized, Quadruple-Blind, Sham-Controlled Clinical Trial. Neurourol Urodyn. 2025 Jun;44(5):1140-1148. doi: 10.1002/nau.70055. Epub 2025 Apr 14.

MeSH Terms

Conditions

Urinary Incontinence

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PAU

Study Record Dates

First Submitted

November 20, 2020

First Posted

November 25, 2020

Study Start

January 1, 2021

Primary Completion

February 1, 2023

Study Completion

April 15, 2023

Last Updated

November 1, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Available IPD Datasets

Study Protocol Access

Locations